Human CXCL16 Protein, Fc Tag
分子別名(Synonym)
CXCLG16, SR-PSOX, SRPSOX, C-X-C motif chemokine ligand 16
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human CXCL16, Fc Tag (CX6-H5254) is expressed from human 293 cells (HEK293). It contains AA Asn 30 - Thr 205 (Accession # Q9H2A7-1).
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 45.7 kDa. The protein migrates as 60-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
該基因編碼的蛋白質(zhì)是一種G蛋白偶聯(lián)受體,具有七個(gè)跨膜結(jié)構(gòu)域,屬于CXC趨化因子受體家族。該家族還包括CXCR1、CXCR2、CXCR3、CXCR4、CXCR5和CXCR7。該基因映射到趨化因子受體基因簇,在幾個(gè)T淋巴細(xì)胞亞群和骨髓基質(zhì)細(xì)胞中表達(dá)。編碼的蛋白質(zhì)及其唯一配體趨化因子配體16(CCL16)是調(diào)節(jié)T淋巴細(xì)胞向各種外周組織(肝、脾紅髓、腸、肺和皮膚)遷移的信號(hào)通路的一部分,并促進(jìn)細(xì)胞與樹(shù)突狀細(xì)胞和成纖維網(wǎng)狀細(xì)胞的相互作用。CXCR6/CCL16還控制駐留記憶T淋巴細(xì)胞在肺部不同部位的定位,并維持氣道駐留記憶T細(xì)胞,這是抵抗呼吸道病原體的重要第一道防線(xiàn)。編碼的蛋白質(zhì)充當(dāng)HIV-1和SIV與CD4結(jié)合進(jìn)入靶細(xì)胞的進(jìn)入輔助受體。
關(guān)鍵字: CXCL16;CXCL16蛋白;CXCL16重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶(hù)超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。